Merck's Gerberding discusses advantages, challenges of vaccines

Eighteen months ago, Julie Gerberding left her position as CDC director to head up Merck's vaccine unit, which is responsible for making 14 of the 17 vaccines recommended for kids and nine of the 10 shots adults should received. Once an undesirable area of industry, vaccine development has enjoyed an renaissance over the last several years as drugmakers employ new technology to access lucrative markets. In a interview with Xconomy, Gerberding explores the advantages and challenges vaccines present to Big Pharma. Report

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.